NCT03907969: A Clinical Trial to Evaluate AZD7648 Alone and in Combination With Other Anti-cancer Agents in Patients With Advanced Cancers

NCT03907969
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Serine-Threonine Kinase Inhibitor, Chemotherapy, Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 130 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with untreated, symptomatic, unstable brain metastases – see trial for details
https://ClinicalTrials.gov/show/NCT03907969

Comments are closed.

Up ↑